Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2023 Annual Meeting | Industry Therapeutic Update from Azurity Pharmaceuticals: Restless Legs Syndrome Updated Guidelines and Management Strategies for Improved Patient Outcomes

Tuesday 04/25/23
06:00 PM - 09:00 PM EST Add To Calendar
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
John Winkelman
General Neurology, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-rehabilitation
Dr. Winkelman will describe revised treatment guidelines from the Restless Legs Syndrome Foundation which, based on recent evidence related to both efficacy and safety, describe a paradigm shift in the treatment of Restless Legs Syndrome (RLS). It is now recommended that dopaminergic agents (DAs) should no longer be first-line treatments for chronic persistent RLS due to their propensity to worsen RLS symptoms over time (augmentation). Rather, calcium channel α2δ ligands (A2Ds) or iron (in those with appropriate iron indices) are now considered initial treatments. He will also review the diagnostic criteria for RLS, the FDA-approved medications for RLS, and the features of dopaminergic augmentation of RLS. Dr. Winkelman will conclude with a Q&A session to give attendees the opportunity to ask questions.


Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2023 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 09:00 PM EST Speaker Industry Therapeutic Update from Azurity Pharmaceuticals: Restless Legs Syndrome Updated Guidelines and Management Strategies for Improved Patient Outcomes
Faculty Disclosures
John Winkelman No disclosure on file